Center for Cancer Biomarkers CCBIO and Gade Laboratory of Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
Acta Obstet Gynecol Scand. 2024 Jan;103(1):165-175. doi: 10.1111/aogs.14689. Epub 2023 Oct 15.
Vulva squamous cell carcinoma (VSCC) develops through two separate molecular pathways-one involving high-risk human papilloma virus infection (HPV-associated), and the other without HPV infection (HPV-independent) often involving TP53 mutation. HPV-associated VSCC generally has a better progression-free survival than HPV-independent VSCC. The aim of this study was to determine TP53 mutation status using immunohistochemistry, compare different methods of HPV detection and correlate both with survival in a retrospective cohort of 123 patients with VSCC.
Immunohistochemistry for p53, Ki67 and p16 (a surrogate marker for HPV infection) was performed on formalin-fixed paraffin-embedded tissues from a cohort of surgically treated VSCC patients to identify molecular subtypes of VSCC. Presence of HPV infection was detected by HPV DNA PCR and HPV mRNA in situ hybridization (ISH). The Pearson chi-square test and multivariable Cox regression model were used to investigate the association of different parameters with progression-free survival and disease-specific survival (DSS), and Kaplan-Meier curves were used to show the association of different parameters with survival.
The results of p53 and p16 immunohistochemistry confirmed three VSCC subtypes associated with different prognosis. The TP53 mutation status was identified as an independent prognostic factor of worse progression-free survival (p = 0.024) after adjustment for FIGO stage. p16 immunohistochemistry, mRNA ISH, and DNA PCR had excellent concordance in terms of HPV detection. According to the multivariable Cox regression model, the presence of hrHPV mRNA correlated significantly with increased progression-free survival (p = 0.040) and DSS (p = 0.045), after adjustment for other confounders.
p53 and p16 immunohistochemistry stratify VSCC cohort into three subtypes with TP53mutated patients having the worst prognosis. The detection of hrHPV mRNA by ISH was an independent predictor of increased survival. Thus, the combined detection of p53 and HPV mRNA might improve risk stratification in VSCC.
外阴鳞状细胞癌(VSCC)通过两种不同的分子途径发展——一种涉及高危型人乳头瘤病毒感染(HPV 相关),另一种不涉及 HPV 感染(HPV 不相关),通常涉及 TP53 突变。HPV 相关 VSCC 的无进展生存期通常优于 HPV 不相关 VSCC。本研究旨在通过免疫组织化学检测 TP53 突变状态,比较 HPV 检测的不同方法,并在回顾性队列中分析 123 例 VSCC 患者的生存情况。
对接受手术治疗的 VSCC 患者队列的福尔马林固定石蜡包埋组织进行 p53、Ki67 和 p16(HPV 感染的替代标志物)免疫组化,以确定 VSCC 的分子亚型。通过 HPV DNA PCR 和 HPV mRNA 原位杂交(ISH)检测 HPV 感染的存在。采用 Pearson 卡方检验和多变量 Cox 回归模型分析不同参数与无进展生存期和疾病特异性生存期(DSS)的关系,Kaplan-Meier 曲线显示不同参数与生存的关系。
p53 和 p16 免疫组化的结果证实了三种与不同预后相关的 VSCC 亚型。TP53 突变状态被确定为无进展生存期更差的独立预后因素(p=0.024),在调整 FIGO 分期后。p16 免疫组化、mRNA ISH 和 DNA PCR 在 HPV 检测方面具有极好的一致性。根据多变量 Cox 回归模型,在调整其他混杂因素后,hrHPV mRNA 的存在与无进展生存期(p=0.040)和 DSS(p=0.045)的增加显著相关。
p53 和 p16 免疫组化将 VSCC 队列分为三种亚型,TP53 突变患者的预后最差。ISH 检测 hrHPV mRNA 是生存增加的独立预测因子。因此,p53 和 HPV mRNA 的联合检测可能会改善 VSCC 的风险分层。